These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29920491)

  • 1. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
    ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
    Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
    Chang H; Samiee S; Yi QL
    Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
    Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
    J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
    Straka C; Knop S; Vogel M; Müller J; Kropff M; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Salwender H; Wandt H; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Fischer T; Liebisch P; Engelhardt M; Einsele H
    Eur J Haematol; 2019 Sep; 103(3):255-267. PubMed ID: 31231828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
    Okura M; Ida N; Yamauchi T
    Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation.
    Wang H; Zhou X; Zhu JW; Ye JN; Guo HF; Sun C
    Oncol Lett; 2018 Nov; 16(5):5655-5666. PubMed ID: 30344721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
    Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
    Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
    Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma.
    Pozdnyakova O; Morgan EA; Li B; Shahsafaei A; Dorfman DM
    Leuk Lymphoma; 2012 Oct; 53(10):1905-10. PubMed ID: 22423624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
    Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
    Minoia C; Pisapia G; Palazzo G; Ingrosso C; Buonanno M; Spinosa C; Prudenzano A; Pricolo G; Mazza P
    Bone Marrow Transplant; 2015 Nov; 50(11):1486. PubMed ID: 26281030
    [No Abstract]   [Full Text] [Related]  

  • 18. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
    Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
    Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
    J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
    Hu K; Wang J; Zhu MX; Wang YF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.